Raptor's Intellectual Property

Raptor's Issued Patents

RAP chemotherapeutic conjugates, composition of matter; U.S. 7,700,554; 4/20/2010
Methods of treating neuronal conditions with RAP-based conjugates; 7,560,431; 7/14/09 also under prosecution in Japan, Hong Kong, Australia, Canada and Europe
Methods of treating neuronal conditions with RAP-based conjugates; 7,569,544; 8/4/09
RAP conjugates, broad composition of matter; U.S. 7,829,537; 11/9/2010
Methods of modulating entry of p97 to the brain; E.U. 1554572; 10/14/09; also Japan 4202250; 10/17/08
RAP variants, composition of matter; Australia, 2002322720; 2/26/09

Receptor-selective RAP variants, composition of matter; 11/576,502 filed 4/2/2007 also under prosecution in Europe and Japan
Methods of treating liver disorders with RAP conjugates; 12/441,618 filed 9/18/2007 also under prosecution in Europe, Canada, China, Hong Kong, Japan, Korea and Mexico
Structurally stabilized, cyclized RAP variants, composition of matter; 12/600,786 filed 3/21/08 also under prosecution in Europe, Canada, China, Brazil, India, Japan, Korea and Mexico
4-methylpyrazole formulations for inhibiting ethanol intolerance; 12/797,594 filed 6/9/2010 also under prosecution in Taiwan
Genotype specific methods for treating human subjects using 4-methylpyrazole; PCT/US2010/ 037879 filed 6/9/2010 also under prosecution in Taiwan
4-methylpyrazole formulations; PCT/US2010/ 059065 filed 12/6/2010 also under prosecution in Taiwan
Protopanaxadiol-type ginsenoside compositions and uses thereof; 12/863,979 filed 7/21/2010 national stage entry in US, Europe, Canada, Japan, Australia, New Zealand, Singapore, India, Indonesia, Philippines, Thailand, China, South Korea, Vietnam, Malaysia, also under prosecution in Taiwan
Method for treating liver disorder with receptor associated protein (RAP) peptide-fucosidase inhibitor; PCT/US2011/022917 filed 1/28/11
Use of cysteamine dioxgenase inhibitor to improve cysteamine treatment; PCT/US61/617,867 filed 3/30/12

Enterically coated cystamine, cysteamine and derivatives thereof; U.S. 11/990,869; 6/27/11; invented by Ranjan Dohil and Jerry Schneider; assigned to the University of California at San Diego, also being prosecuted in Australia, Brazil, Canada, Chile, Colombia, Eurasia, Europe, India, Israel and Mexico
Treatment of Non-Alcoholic Steatohepatitis (NASH) Using Cysteamine Compounds; U.S. 12/745,504; 6/24/11; invented by Ranjan Dohil and Jerry Schneider; assigned to the University of California at San Diego, also being prosecuted in Argentina, Australia, Brazil, Canada, Chile, China, Europe, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, New Zealand, Russia, Singapore, South Africa, Thailand and Taiwan.
Method and compositions for treating diseases mediated by transglutaminase activity (including use of cystamine); U.S. 6,794,414; 9/21/2004
Remedy for CAG repeat expansion diseases (including use of cystamine); U.S. 6,355,690; 3/12/2002

Method of inhibiting platelet aggregation with glutamate receptor antagonists; PCT/US08/00559 filed 1/16/2008; inventors Charles Lowenstein and Craig Morrell; assigned to Johns Hopkins University
Methods of treating cancer with Mesd or peptides derived from Mesd; PCT/US08/62092 filed 4/30/2008; invented by Guojun Bu; assigned to Washington University in Saint Louis